Date: 2016-10-26
Type of information: Development agreement
Compound: antibody-drug conjugates for treating leukemias
Company: Nordic Nanovector (Norway) Heidelberg Pharma (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: antibody drug conjugate (ADC)
Disease: leukemia
Details: * On October 26, 2016, Nordic Nanovector announced it has entered into a collaboration with Heidelberg Pharma GmbH, a subsidiary of biopharmaceutical company Wilex specializing in the development of antibody-drug conjugates (ADCs), to develop novel ADCs for treating leukaemias. This collaboration is part of Nordic Nanovector’s strategy to develop its pipeline of targeted therapies to include antibody products conjugated to anti-cancer compounds that are not radionuclides.
Financial terms:
Latest news:
